SEC Form 3 · accession 0001209191-17-010088
Viridian Therapeutics, Inc.\DE · VRDN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Remeditex Ventures LLC
10% Owner
Period of report
Feb 13, 2017
Accepted (ET)
Feb 13, 2017 · 5:29 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001590750
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | holding | — | — | — | 2,706,563 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Shares of common stock of the corporation then known as Miragen Therapeutics, Inc. ("Old Miragen") were converted into shares of the Issuer pursuant to that certain Agreement and Plan of Merger and Reorganization, dated as of October 31, 2016, by and among the Issuer, Signal Merger Sub, Inc. and Old Miragen (the "Merger Agreement"). Pursuant to the terms of the Merger Agreement, each share of common stock was converted into 0.7031 shares of the Issuer's common stock.
- F2Represents 3,849,471 shares of common stock of Old Miragen prior to conversion pursuant to the Merger Agreement including: 797,308 shares of common stock of Old Miragen; and shares of common stock of Old Miragen issued upon the conversion of 1,083,333 shares of Series B preferred stock of Old Miragen and 1,968,830 shares of Series C preferred stock of Old Miragen. Immediately prior to the effective time of the merger, each share of Old Miragen preferred stock converted into one share of Old Miragen's common stock.
Remarks
Exhibit List: Exhibit 24 - Power of Attorney